Key Takeaways FOLD posted Q2 EPS of $0.01, missing estimates. Revenues rose 22$154.7M, topping expectations.Galafold sales hit $128.9M, up 12$25.8M in Q2.FOLD kept its 2025 view unchanged, targeting 15-22% revenue growth and GAAP profitability in the second half.Amicus Therapeutics (FOLD) reported adjusted earnings of 1 cent per share for the second quarter of 2025, which missed the Zacks Consensus Estimate of 2 cents. The company had incurred a loss of 6 ...